You are here: Home > News > Health > Article
Home
Business & Finance
News
U.S.
Politics
International
Technology
Entertainment
Sports
Lifestyle
Oddly Enough
Health
Science
Special Coverage
Video
Pictures
Your View
The Great Debate
Blogs
Weather
Reader Feedback
Do More With Reuters
RSSRSS Feed
Widgets
Mobile
Podcasts
Newsletters
Your View
Partner Services
CareerBuilder
Affiliate Network
Professional Products
Support (Customer Zone)
Reuters Media
Financial Products
About Thomson Reuters

Bayer gets Japan approval for kidney cancer drug

Mon Jan 28, 2008 7:00am EST
 
[-] Text [+]

TOKYO (Reuters) - German drug maker Bayer AG said on Monday that its drug Nexavar had been approved in Japan for the treatment of kidney cancer.

Last week, Japanese health authorities granted priority review status for Nexavar to treat liver cancer.

(Reporting by Edwina Gibbs)

 

Special Coverage

Dr. Qurrath U. Ain of the Elmhurst Pediatric Emergency Center examines a patient with flu-like symptoms at Elmhurst Hospital in New York in this December 12, 2003. file photo. REUTERS/Shannon Stapleton/Files
Healthcare Reform

Reuters provides an in-depth look at the issues facing Americans as the Obama administration wrestles with healthcare policy.  Full Coverage 

Photo

Editor's Choice

An Orangeman walks past an electric plaque of Britain's Queen Elizabeth in Belfast Orange Lodge July 13, 2009. REUTERS/Cathal McNaughton SlideshowSlideshow 

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video

Healthcare Reform

Uninsured patient Josefa Martinez, 8, has her blood pressure measured during a health check-up at Venice Family Clinic in Venice, California, June 25, 2009. REUTERS/Lucy Nicholson
The healthcare disconnect

A successful reform package will have to address the cost for services for private versus public providers and employ innovative technological advances, writes Darrell West, author of Digital Medicine: Health Care in the Internet Era.  Commentary | Full Coverage 

We want to hear from you

Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better

Please take a moment to complete our survey